Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Turn Therapeutics Inc.NASDAQ: TTRX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income of -$1.25M in Q1 FY2026
Q1 FY2026 operating income was -$1.25M. Trailing-twelve-month operating income was -$6.72M.
Context
- Operating income grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -226.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.25M+43.2% QoQ
- Last fiscal yearDec 2025
- -$5.86M-226.0% YoY
- LTMMar 2026
- -$6.72M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +100.0% | — |
| 1 year | -226.0% | +100.0% | +326.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (5.86M) USD
- Year-over-year change
- -226.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.86M) | -226.0% |
| FY2024 | 2024-12-31 | (1.8M) | +22.1% |
| FY2023 | 2023-12-31 | (2.31M) | — |
Operating Income vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 operating income of -$6.72M is the 2nd highest of the 9 companies compared; the peer median is -$37.57M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.2M | +108.1% | — | 6.6% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$6.72M | — | — | — |
| LTM Apr 2026 | -$10.68M | +18.8% | — | — | |
| LTM Mar 2026 | -$21.89M | -34.8% | — | — | |
| LTM Mar 2026 | -$32.31M | -71.6% | — | — | |
| LTM Mar 2026 | -$42.84M | +20.1% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$43.03M | +33.1% | — | 359.1% |
| LTM Mar 2026 | -$55.59M | -44.8% | — | — | |
| LTM Mar 2026 | -$74.65M | +22.0% | — | 496.4% | |
| Peer median (excluding TTRX) | -$37.57M | +19.5% | — | 359.1% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 7.5K | 245.96K | 265.57K |
| Selling, General & Admin | 2.3M | 1.55M | 5.59M |
| Operating Expenses | 2.31M | 1.8M | 5.86M |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| EBITDA | (2.25M) | (1.72M) | (3.14M) |
| EBITDA Margin | — | — | — |
| Operating Income | (2.31M) | (1.8M) | (5.86M) |
| Operating Margin | — | — | — |
| Interest Income | 15.88K | 28.71K | 29.58K |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 15.88K | 28.71K | 2.66M |
| Income Before Tax | (2.29M) | (1.77M) | (3.19M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.17) | (0.13) | (0.23) |
| EPS (Diluted) | (0.17) | (0.13) | (0.23) |
| Weighted Avg Shares | 13.25M | 13.42M | 13.74M |
| Weighted Avg Shares (Diluted) | 13.25M | 13.42M | 13.74M |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.